title: Entacapone-induced hepatotoxicity and hepatic dysfunction.
abstract: We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports.
authors.affiliation: Department of Geriatric Medicine, The Canberra Hospital, Canberra, Australia.
authors.forename: Alexander
authors.initials: A
authors.lastname: Fisher
authors.forename: James
authors.initials: J
authors.lastname: Croft-Baker
authors.forename: Michael
authors.initials: M
authors.lastname: Davis
authors.forename: Patrick
authors.initials: P
authors.lastname: Purcell
authors.forename: Allan J
authors.initials: AJ
authors.lastname: McLean
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D009570:Nitriles; C071192:entacapone